CR10849A - Derivados de benzamida como agonistas del receptor ep4 - Google Patents

Derivados de benzamida como agonistas del receptor ep4

Info

Publication number
CR10849A
CR10849A CR10849A CR10849A CR10849A CR 10849 A CR10849 A CR 10849A CR 10849 A CR10849 A CR 10849A CR 10849 A CR10849 A CR 10849A CR 10849 A CR10849 A CR 10849A
Authority
CR
Costa Rica
Prior art keywords
benzamida
agonists
derivatives
receiver
Prior art date
Application number
CR10849A
Other languages
English (en)
Inventor
Alessandra Gaiba
Mark Patrick Healy
Christopher Norbert Johnson
Susan Roomans
Steven James Stanway
Martin Edward Swarbrich
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0625098A external-priority patent/GB0625098D0/en
Priority claimed from GB0715145A external-priority patent/GB0715145D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR10849A publication Critical patent/CR10849A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
CR10849A 2006-12-15 2009-06-09 Derivados de benzamida como agonistas del receptor ep4 CR10849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0625098A GB0625098D0 (en) 2006-12-15 2006-12-15 Novel compounds
GB0715145A GB0715145D0 (en) 2007-08-03 2007-08-03 Novel compounds

Publications (1)

Publication Number Publication Date
CR10849A true CR10849A (es) 2009-08-12

Family

ID=39149241

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10849A CR10849A (es) 2006-12-15 2009-06-09 Derivados de benzamida como agonistas del receptor ep4

Country Status (21)

Country Link
US (3) US8314147B2 (es)
EP (1) EP2101751A1 (es)
JP (1) JP5069752B2 (es)
KR (1) KR20090089868A (es)
AR (1) AR064361A1 (es)
AU (1) AU2007331471C1 (es)
BR (1) BRPI0720254A2 (es)
CA (1) CA2672631A1 (es)
CL (1) CL2007003640A1 (es)
CR (1) CR10849A (es)
DO (1) DOP2009000124A (es)
EA (1) EA015931B1 (es)
IL (1) IL198931A0 (es)
MA (1) MA30991B1 (es)
MX (1) MX2009006474A (es)
NO (1) NO20092314L (es)
NZ (1) NZ577109A (es)
PE (1) PE20081579A1 (es)
SG (1) SG177203A1 (es)
TW (1) TW200848014A (es)
WO (1) WO2008071736A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172447A4 (en) * 2007-07-03 2011-08-24 Astellas Pharma Inc amide
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
ES2471919T3 (es) * 2007-12-19 2014-06-27 Amgen, Inc Derivados de ácido fenilac�tico como moduladores de inflamación
ES2518919T3 (es) * 2008-05-14 2014-11-05 Astellas Pharma Inc. Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética
GB0810313D0 (en) * 2008-06-05 2008-07-09 Glaxo Group Ltd Novel compounds
GB0810617D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
CN104292154A (zh) * 2009-09-29 2015-01-21 葛兰素集团有限公司 新化合物
ES2512727T3 (es) * 2009-09-29 2014-10-24 Glaxo Group Limited Nuevos compuestos
US20120190637A1 (en) 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
CN103068382A (zh) * 2010-07-30 2013-04-24 阿勒根公司 用于皮肤修复的化合物和方法
US8926963B2 (en) 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012039972A1 (en) 2010-09-21 2012-03-29 Eisai R&D Management Co., Ltd. Pharmaceutical composition
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
WO2013123275A1 (en) * 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
CA2997692A1 (en) * 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Crystalline forms of grapiprant
EP3245186A1 (en) 2015-01-16 2017-11-22 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Method to prepare phenolics from biomass
EP3184505A1 (en) 2015-12-22 2017-06-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Method for preparing phenolics using a catalyst
WO2020209576A1 (ko) * 2019-04-09 2020-10-15 경희대학교 산학협력단 척수 손상 또는 척추관 협착증의 예방 또는 치료용 약제학적 조성물
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
CN111454150B (zh) * 2019-12-25 2023-03-28 南京工业大学 一种(s)-2-芳基丙酸酯类化合物的合成方法
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
AUPO713297A0 (en) 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (en) 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
CA2346038A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
ATE336247T1 (de) 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
BR0309200A (pt) 2002-04-12 2005-02-22 Pfizer Uso de ligandos receptores ep4 no tratamento de doenças envolvidas com a il-6
AU2003237520B2 (en) 2002-06-10 2009-01-08 Laboratoires Serono Sa Gamma lactams as prostaglandin agonists and use thereof
WO2004037813A1 (en) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2511255C (en) 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
CN100408570C (zh) 2003-01-29 2008-08-06 阿斯特兰德英国有限公司 Ep4受体拮抗剂
CA2536870C (en) 2003-09-03 2009-10-27 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7326732B2 (en) * 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
AU2005238291A1 (en) 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
KR20070006890A (ko) * 2004-05-04 2007-01-11 화이자 인코포레이티드 오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물
WO2005116010A1 (en) 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
ATE533766T1 (de) * 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten

Also Published As

Publication number Publication date
NO20092314L (no) 2009-08-31
US20100022650A1 (en) 2010-01-28
US20080167377A1 (en) 2008-07-10
EP2101751A1 (en) 2009-09-23
AU2007331471C1 (en) 2013-07-25
MX2009006474A (es) 2009-06-26
NZ577109A (en) 2011-12-22
SG177203A1 (en) 2012-01-30
US20130261185A1 (en) 2013-10-03
AR064361A1 (es) 2009-04-01
BRPI0720254A2 (pt) 2014-01-07
AU2007331471A1 (en) 2008-06-19
DOP2009000124A (es) 2010-03-31
EA015931B1 (ru) 2011-12-30
EA200970585A1 (ru) 2009-10-30
MA30991B1 (fr) 2009-12-01
KR20090089868A (ko) 2009-08-24
TW200848014A (en) 2008-12-16
PE20081579A1 (es) 2009-01-01
US8314147B2 (en) 2012-11-20
JP5069752B2 (ja) 2012-11-07
IL198931A0 (en) 2010-02-17
JP2010513242A (ja) 2010-04-30
AU2007331471B2 (en) 2013-01-10
CL2007003640A1 (es) 2008-07-11
CA2672631A1 (en) 2008-06-19
WO2008071736A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
BRPI0914544A2 (pt) derivados de pirimidona substituídos
BRPI1008749A2 (pt) Derivados de benzodiazepina
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
ES2643164T3 (es) Indol 7-sustituido como inhibidores de Mcl-1
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI1016032A2 (pt) conjunto dual de tensionador.
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI0909527A2 (pt) derivados substituídos de 4-aminociclohexano
BR112012008108A2 (pt) derivados de xantina substituídos
BR112012015868A2 (pt) derivados de imidazolidinadiona
BRPI0815135A2 (pt) Derivados de azepina como inibidores de gama secretase.
BRPI1015921A2 (pt) agonistas de gpr119
BRPI0820447A2 (pt) Agonistas do receptor de glicocorticóides
CR20130209A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
DOP2007000068A (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0813768A2 (pt) Derivados de benzazepina úteis como antagonistas de vasopressina